The Acute Respiratory Failure drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Respiratory Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Respiratory Failure. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Respiratory Failure and features dormant and discontinued products.
GlobalData tracks five drugs in development for Acute Respiratory Failure by five companies/universities/institutes. The top development phase for Acute Respiratory Failure is phase ii with five drugs in that stage. The Acute Respiratory Failure pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Acute Respiratory Failure pipeline products market are: Asklepion Pharmaceuticals, AstraZeneca and Genentech USA.
The key targets in the Acute Respiratory Failure pipeline products market include L-Citrulline, Interleukin 33 (Interleukin 1 Family Member 11 or IL1F11 or Nuclear Factor From High Endothelial Venules or NFHEV or IL33), and Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA).
The key mechanisms of action in the Acute Respiratory Failure pipeline product include Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) Antagonist with one drug in Phase II. The Acute Respiratory Failure pipeline products include six routes of administration with the top ROA being Intravenous and four key molecule types in the Acute Respiratory Failure pipeline products market including Monoclonal Antibody, and Recombinant Enzyme.
Acute Respiratory Failure overview
Acute respiratory failure is when lungs become suddenly unable to provide enough oxygen to the blood. Symptoms of respiratory failure include shortness of breath, tachypnea, extreme tiredness, heart palpitations, restlessness, and pale skin. It can be caused by insufficient blood flow to the lungs; blockage, scarring, or fluid in the lungs; or inability to breathe. It can be diagnosed by testing the amount of oxygen and carbon dioxide in blood via pulse oximetry and arterial blood gas (ABG) test; X-rays, CT scans, and EKG can also be used for diagnosis. Mechanical ventilation, extracorporeal membrane oxygenation (ECMO), oxygen therapy, and fluids are used for treatment.
For a complete picture of Acute Respiratory Failure’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
